Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02979002
Other study ID # ENSP276/DGDB26012016
Secondary ID
Status Completed
Phase N/A
First received November 29, 2016
Last updated August 6, 2017
Start date December 2016
Est. completion date August 2017

Study information

Verified date August 2017
Source National School of Public Health, Morocco
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to estimate the accuracy of CL Detect Rapid Testâ„¢ compared to a composite reference standard test (Direct examination of skin smears + PCR test) in patients with clinically suspected Cutaneous Leishmaniasis disease in Morocco.


Description:

Study participants are recruited in nine health centers located in fourthree CL endemic provinces. The RDT under evaluation (index test) is the CL Detectâ„¢ Rapid Test (InBios, USA); a membrane-based amastigote antigen (peroxidoxin) detection test. The reference standard consists of two tests: direct examination of skin smears and PCR. For each patient, the health professional takes one dental broach sample and four skin smear samples from a single lesion. The dental broach sample is used for the RDT, which is done once. The skin smear samples are sent to provincial laboratories for microscopy testing and to reference laboratories in Morocco and Belgium for PCR testing by ITS1 PCR, Hsp70 genotyping and parasite load determination. Readers of index and reference tests do not have access to clinical information or any other test results. The results of the test under evaluation (RDT) and the molecular tests (PCR) are not communicated to the patient or her/his physician, as case management has to follow current clinical guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 219
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria:

- Participants with suspected Cutaneous Leishmaniasis wound(s) in apparently healthy state

- Who is able to learn the Information sheet and sign the Informed consent form by them selves or by their parents with the presence or not of a witness (for illiterate people)

- Who satisfy the following criteria :

- with an ulcerative lesion in any accessible part of the body to perform the dental broach and the scraping.

- Just one ulcerative lesion by patient could be selected (The newest and the less infected)

- Lesion should be less than 04 months of age

Exclusion Criteria:

- Patients with only nodular, papular, macular or nodulo-papular suspected CL forms

- Patients with ulcerative lesions with a suspected bacteria origin which could disappear after a short course of antibiotic treatment.

- Patients who already received during the last two months, prior to signing the consent, a physical treatment (e.g. cryotherapy, thermotherapy, Laser) or a traditional treatment (e.g. burn, acide, traditional scraping)

- Patients presenting other disease with the need to take anti-parasite treatments

- Patient with a acute or chronic disease needing hospitalization

- Patient who already received antimoniate treatment incomplete or complete duration and dose against CL

- Any situation that could engage the security of the patient or of the health professional (e.g. People with a psychiatric trouble or a mental handicap )

- For children less than 12 years old, the decision of participation is mainly based on the condition that their parents are able to learn and understand the information sheet and sign the informed consent form

Study Design


Locations

Country Name City State
Morocco Primary Health Center Boumalne Tinghir
Morocco Primary Health center Erfoud Errachidia
Morocco Primary Health Center Kelaat Mgouna Tinghir
Morocco Primary Health Center Sefrou
Morocco Primary Health Center Sekoura Ouarzazates
Morocco Primary Health Center Sidi Kacem
Morocco Primary Health Center Tarmight Ouarzazates
Morocco Primary Health Center Tazouta Sefrou
Morocco Health primary center Tinejdad Errachidia

Sponsors (2)

Lead Sponsor Collaborator
National School of Public Health, Morocco Institute of Tropical Medicine, Belgium

Country where clinical trial is conducted

Morocco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive result for this test 50 minutes
See also
  Status Clinical Trial Phase
Completed NCT01988909 - WR 279,396 for the Treatment of Cutaneous Leishmaniasis Phase 2
Enrolling by invitation NCT00840359 - Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Phase 2
Enrolling by invitation NCT00737386 - Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank N/A
Completed NCT00233545 - Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Phase 2
Completed NCT01462500 - Pharmacokinetics of Miltefosine in Children and Adults Phase 4
Completed NCT01011309 - A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Phase 2
Completed NCT01301924 - Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Phase 2/Phase 3
Not yet recruiting NCT02281669 - Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients N/A
Completed NCT01464242 - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT01790659 - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Phase 3
Completed NCT01050907 - Miltefosine to Treat Mucocutaneous Leishmaniasis Phase 2
Completed NCT04340128 - Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Phase 3
Terminated NCT00317629 - Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Phase 3
Completed NCT00351520 - Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Phase 3
Completed NCT01381055 - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT01050777 - Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Phase 0
Completed NCT01380314 - Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Phase 2
Terminated NCT01380301 - Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony Phase 2
Completed NCT00703924 - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Phase 2
Completed NCT00344084 - Surveillance for Leishmaniasis Skin Lesions in Mali